ClinicalTrials.gg
WithdrawnNCT06878833Starlyng-2Updated Apr 8, 2025

A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder

A Phase 3 interventional study of LYN-005 (risperidone) and Placebo for LYN-005 in Schizophrenia and Schizoaffective Disorder, sponsored by Lyndra Inc.. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Lyndra Inc. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor stopped operations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
120th of 123
0 · median 100
Started
2025
the only one that year
Phase 3
34 of 127
2 open now
Registered
125th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 120th largest by enrollment of the 123 interventional ones that give a count, is the only one that started in 2025, is one of 34 in phase 3, and was the 125th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

Lyndra Therapeutics, Inc., is developing a long-acting oral (LAO) treatment of risperidone (LYN-005) in a capsule dosage form (LYNX® drug delivery platform). The intent of LYN-005 is to reduce the dosing frequency of orally-administered risperidone to once weekly or less and, thereby improve treatment adherence and management of schizophrenia and schizoaffective disorder.

This study will evaluate the safety and tolerability of multiple administrations of LYN-005 at 3 dose levels.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Schizophrenia
  • Schizoaffective Disorder
  • Risperidone
  • LYN-005
  • long-acting oral (LAO) therapy
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged ≥18 and ≤65 years.
  2. Current diagnosis of schizophrenia or schizoaffective disorder according to version 5 (DSM-5) criteria as confirmed by the Mini International Neuropsychiatric Interview version 7.0.2 (MINI 7.0.2).
  3. Psychiatric criteria:

    1. Duration of diagnosis of schizophrenia or schizoaffective disorder for ≥2 years.
    2. Outpatient; not hospitalized for worsening of schizophrenia within the last 6 months (partial hospitalization for social management within this time period is acceptable).
    3. Medically stable over the last month and psychiatrically stable without significant symptom exacerbation over the last 3 months.
  4. Stabilized on a therapeutic dose of an oral antipsychotic drug for a minimum of 6 weeks at the time of Screening.
  5. On a stable dosage of all permitted non-antipsychotic medications (except for medication to be used on an as-needed basis) for at least 1 month before the Screening visit and for the duration of the study.
  6. Clinical Global Impression-Severity (CGI-S) score of ≤4 (moderately ill) at Screening and Day -7.
  7. Positive and Negative Syndrome Scale (PANSS) score of ≤80 points at Screening.
  8. (BMI) of ≥18 kg/m2 and ≤38 kg/m2.
  9. Able to read and understand study procedures and provide written before the initiation of any protocol-specific procedures.
  10. Willing to comply with all protocol-specified procedures and availability for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  1. Participants with known esophageal or GI disease, including but not limited to:

    1. Known strictures such as esophageal web, pyloric stenosis, or small intestinal stricture, or participants with high risk of stricture, e.g., Crohn's disease.
    2. Prior varices or small or large bowel obstructions.
    3. Prior abdominal or upper gastrointestinal surgery including gastric bypass or removal of a significant portion of the gastrointestinal (GI) tract that may impose a high risk of strictures (prior uncomplicated laparoscopic procedures including appendectomy or colectomy are permitted).
    4. History of diarrhea or constipation within 3 months of Screening that in the opinion of the investigator would be considered clinically significant.
    5. Multiple episodes of moderate or severe abdominal pain within 3 months of Screening.
    6. History of moderate to severe Acid Reflux Disease or a score of ≥2 on the Acid Reflux Severity Scale (ARSS) [2], indicating moderate to severe symptoms.
  2. PILL-5 questionnaire score of 5 or greater.
  3. Any clinically significant medical, surgical or psychiatric condition that in the opinion of the investigator would exclude them from the study, including:

    1. Presence of an uncontrolled, unstable, clinically significant medical condition that could put the participant at risk because of participation in the study, interfere with the participant's ability to participate in the study or influence the interpretation of safety or pharmacokinetic (PK) evaluations.
    2. History of a major cardiovascular event (myocardial infarction, cardiac surgery or revascularization, unstable angina, stroke, or ) or a hospitalization for heart failure within 6 months of Screening.
    3. Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of Screening.
    4. Known status, including individuals who have undergone organ transplantation, on immunosuppression for an immune mediated disease, or are positive for (HIV).
    5. Positive test for active or C at Screening. Participants with successfully treated hepatitis B infection which has been resolved for greater than 1 year or successfully treated infection will not be excluded.
    6. Have donated more than 250 mL of blood within 30 days of Screening.
    7. Have difficulties with venipuncture/cannulation, including difficulty accessing veins for blood sampling and/or history of coagulopathy or endocarditis.
    8. Current diagnosis of major depressive episode, panic disorder, agoraphobia, social anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder on the MINI 7.0.2 or in the judgment of the Investigator. (Note that individuals with depression secondary to schizoaffective disorder are eligible).
    9. Suicidal ideation associated with actual intent and a method or plan in the past 6 months, as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS; i.e., "Yes" answers on items 4 or 5) at Screening and Day -7or having made a suicide attempt within the last 2 years.
    10. Known or suspected (non-febrile) seizure disorder.
    11. History of neuroleptic malignant syndrome
    12. Current or history of clinically significant tardive dyskinesia.
    13. Known or suspected diagnosis of intellectual disability or organic brain disorder or other diagnosis that is primarily responsible for current symptoms and functional impairment.
    14. Medically non-adherent in the management of their schizophrenia/schizoaffective disorder.
  4. Use of the below medications/treatments in the 2 weeks before enrollment:

    1. Proton pump inhibitors or H2 blockers.
    2. Prokinetic agents.
    3. Medications that may interfere with the absorption, metabolism, or excretion of risperidone, e.g.: i. Drugs metabolized via Cytochrome P450 3A4 () pathway, such as macrolide antibiotics and azole antifungals; ii. Moderate or strong CYP3A4 p-glycoprotein (P-gp) enzyme inducers and inhibitors (carbamazepine, phenytoin, rifampicin, phenobarbital, itraconazole, verapamil); iii. Moderate or strong Cytochrome P450 2D6 (CYP2D6) inhibitors (e.g., fluoxetine, fluoxetine combinations, paroxetine, or quinidine).
    4. Concomitant medications, natural remedies, supplements, or vitamins that are associated with changes to gastric motility or pH. Use of antacids is permissible, except within 2 hours of dosing with LYN-005.
    5. Use of more than one antidepressant for the treatment of depression; or if on just one, a change in dose within 6 weeks of Screening.
    6. Depot antipsychotic use within 6 months of Screening.
    7. Electroconvulsive therapy within 3 months of Screening.
  5. Participants with clinically significant abnormal safety (e.g. physical examination, vital sign) or safety laboratory assessments, specifically:

    1. Presence of a clinically significant abnormal laboratory result on blood or urine safety tests at Screening.
    2. Anemia ( below lower limit of normal reference range) at Screening.
    3. (ALT), aspartate aminotransferase (AST) ≥3.0 × (ULN), or total ≥1.5 × ULN.
    4. Moderate or severe renal insufficiency at Screening ( \<60 mL/min, as determined the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation).
    5. Heart rate of \<50 beats per minute (bpm) at Screening.
    6. Systolic blood pressure \<100 or ≥150 mmHg and/or diastolic blood pressure \<60 mmHg or ≥100 mmHg, and/or orthostatic hypotension, at Screening.
    7. ≥6.5% at Screening.
    8. Positive fecal occult blood test at Screening.
    9. Clinically significant prolactin elevation (≥200 ng/mL for females; ≥100 ng/mL for males).
  6. The following specified patterns of substance use at Screening:

    1. Fulfillment of the DSM-5 criteria for moderate or severe substance use disorder (excluding nicotine and caffeine) within 6 months of Screening.
    2. History of alcohol consumption exceeding moderate use; in males exceeding 21 units per week and in females exceeding 14 units per week (1 unit = 360 ml beer, 25 mL of 40% spirit or a 125 mL glass of wine) over the past month. Participants are not permitted to consume alcohol during the inpatient stay nor 12 hours before any clinic visit while outpatient.
    3. Positive ethanol breathalyzer.
    4. Positive urine drug screen for substances of abuse other than cannabis at screening or Day -7.
    5. Heavy nicotine use (consumption of >40 cigarettes or >36 mg of nicotine from other sources [e.g., vaping products] daily) or daily use of smokeless tobacco.
  7. Participants of who are (hetero) sexually active but unwilling to use acceptable means of through the End-of-Study. For clarity, participants who are at least 1 year are not of reproductive potential. Acceptable means of contraception include:

    1. Participants who have been surgically sterilized.
    2. Females of reproductive potential: diaphragm, injectable, oral/patch contraceptives for a minimum of 6 weeks, contraceptive sponge, implant, or intrauterine device in use prior to enrollment.
    3. Males: condom in combination with any of the above means of contraception.
    4. All participants: abstinence may be an acceptable means of contraception as long as the individual consents to initiate immediate use of double barrier protection for the duration of the study should (hetero) sexual intercourse occur.
  8. Participants who are nursing or who have positive or indeterminate pregnancy tests at either Screening (serum test) or Day -7 (urine test).
  9. Participants with history of X-ray, computed tomography (CT) scan or angiogram of the abdomen within one year of Screening
  10. Use of any experimental agent within 1 month or 5 half-lives of Screening, whichever is longer.
  11. Employee or immediate family member of employees of the site, Sponsor, or study-related vendors.
  12. History of a serious allergic or reaction to risperidone or LYN-005 (refer to Investigator's Brochure). Previous use of LYN-005 alone, does not exclude participants.
  13. CYP2D6 poor or indeterminate metabolizer status based on genetic testing.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Open Label (OL) Cohort

    After a 7-day run-in period in which participants receive immediate release (IR) risperidone (2 mg/day, 4 mg/day, or 6 mg/day, based on prior antipsychotic drug dose) and a single dose of LYN-005-matched placebo, participants receive weekly doses of 15, 30, or 45 mg of LYN-005 for 7 weeks.

    Drug: LYN-005 (risperidone) · Drug: Placebo for LYN-005 · Drug: IR Risperidone

  • Experimental
    Double Blind (DB) Cohort: LYN-005

    After a 7-day run-in period in which participants receive IR risperidone (2 mg/day, 4 mg/day, or 6 mg/day, based on prior antipsychotic drug dose) and a single dose of LYN-005-matched placebo, participants receive weekly doses of 15, 30, or 45 mg of LYN-005 and daily doses of IR risperidone-matched placebo for 26 weeks.

    Drug: LYN-005 (risperidone) · Drug: Placebo for LYN-005 · Drug: IR Risperidone · Drug: Placebo for IR Risperidone

  • Active comparator
    Double Blind (DB) Cohort: IR Risperidone

    After a 7-day run-in period in which participants receive IR risperidone (2 mg/day, 4 mg/day, or 6 mg/day, based on prior antipsychotic drug dose) and a single dose of LYN-005-matched placebo, participants receive daily doses of 2, 4, or 6 mg IR risperidone and weekly doses of LYN-005-matched placebo for 26 weeks.

    Drug: Placebo for LYN-005 · Drug: IR Risperidone · Drug: Placebo for IR Risperidone

Interventions

  • long-acting oral (LAO) capsule

  • DrugPlacebo for LYN-005

    capsule

  • DrugIR Risperidone

    tablets

  • DrugPlacebo for IR Risperidone

    tablets

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: OL Cohort: Screening through Day 57; DB Cohort: Screening through Day 203

Secondary outcomes

  1. PK Evaluation: Minimum Observed Concentration (Cmin) of Active Moiety at Week 5 (OL Cohort only)

    Time frame: Week 5: postdose: 24 hours (±30 minutes), 48 hours (±30 minutes), 72 hours (±30 minutes), 96 hours (±30 minutes), 120 hours (±30 minutes),144 hours (±30 minutes), and 168 hours (up to 30 minutes before 168 hours)

  2. PK Evaluation: Maximal Observed Concentration (Cmax) of Active Moiety at Week 5 (OL Cohort only)

    Time frame: Week 5: postdose: 24 hours (±30 minutes), 48 hours (±30 minutes), 72 hours (±30 minutes), 96 hours (±30 minutes), 120 hours (±30 minutes),144 hours (±30 minutes), and 168 hours (up to 30 minutes before 168 hours)

  3. PK Evaluation: Average Concentration (Cavg) of Active Moiety at Week 5 (OL Cohort only)

    Time frame: Week 5: postdose: 24 hours (±30 minutes), 48 hours (±30 minutes), 72 hours (±30 minutes), 96 hours (±30 minutes), 120 hours (±30 minutes),144 hours (±30 minutes), and 168 hours (up to 30 minutes before 168 hours)

  4. Change in Structured Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS) Over Time

    Time frame: OL Cohort: Baseline, Day 22 and 43; DB Cohort: Baseline, Days 22, 43, 92, 106, 134, 162, 183

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2025; primary completion for Dec 2026, 20 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 17, 2025
StartEst.
Apr 18, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06878833
Lead sponsor
Lyndra Inc.
Responsible party
Sponsor
First posted
Mar 17, 2025
Start date
Apr 18, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 8, 2025

Study contacts

Nayana Nagaraj
study director · Lyndra Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion